The Clinical Unmet need in the patient with Diabetes and ACS

10' education - Aug. 26, 2017 - Barcelona, Spain - Kausik Ray, MD Imperial College London United Kingdom - PACE-CME symposium held at ESC 2017 - Online CME

This lecture was part of a CME accredited symposium: 'Managing Diabetes & CVD: Is epigenetics a new way forward?' held at ESC 2017 in Barcelona

Video navigation menu

Diabetes is an important CV risk factor that shortens life expectancy 0:16
Lipid-lowering and BP-reduction yield more benefit in diabetes than glucose-lowering 2:23
Some newer antidiabetic drugs may have a broader effect than glucose lowering 4:51
Considering the residual risk, inflammation and the perturbed vasculature may be the next pathways to target in DM 5:52

Educational information

The educational objectives of this symposium were to:

To summarise the epidemiology and pathophysiology of patients at high cardiovascular risk with diabetes
To understand the origin of the high residual cardiovascular risk in patients with diabetes, ACS
To review how BET inhibition affects gene expression via epigenetic mechanisms, as a novel strategy to improve outcomes in CVD
To update and review current clinical research programmes evaluating the role of epigenetic regulation of gene expression in CVD management

Disclosures

Kausik Ray, MD, is cardiologist, and Professor of Public Health/Honorary Consultant Cardiologist at Imperial College London, United Kingdom

CME Accreditation

This programme was accredited by the European Board for Accreditation in Cardiology (EBAC) for 1 hour of external CME credit(s).

Funding

This symposum was supported by an unrestricted educational grant provided by Resverlogix

Online-CME

This is available as accredited online CME for members. Click the button below to enroll:

Enroll

The information and data provided in this program were updated and correct at the time of the program development, but may be subject to change.